Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
arcticnovartis
Tue, 04/29/2025 – 07:03
Read more about Novartis continues strong momentum with double-digit sales g…
Entries by arcticnovartis
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
arcticnovartis
Thu, 04/03/2025 – 02:19
Read more about…
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
arcticnovartis
Mon, 03/31/2025 – 07:04
Read more about Novartis …
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
arcticnovartis
Fri, 03/28/2025 – 17:58
Read more about FDA approves Novartis radioligand thera…
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
arcticnovartis
Tue, 03/25/2025 – 07:18
Read more about Novartis to present new data at AAN, …
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
arcticnovartis
Fri, 03/21/2025 – 00:19
Read more about Novartis receives third FDA approval for oral Fabhalta® (…
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
arcticnovartis
Wed, 03/19/2025 – 14:04
Read more about New Novartis Phase III data demonstr…
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
arcticnovartis
Fri, 03/07/2025 – 15:19
Read more about Novartis shareholders approve all resolutions proposed by the Board of Direc…
Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut
arcticnovartis
Fri, 03/07/2025 – 15:19
Read more about Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrat…
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
arcticnovartis
Fri, 02/28/2025 – 15:04
Read more about Novartis data presentations a…